Skip to Content

Ferro-DSS (docusate / ferrous fumarate) Disease Interactions

There are 5 disease interactions with Ferro-DSS (docusate / ferrous fumarate):

Major

Ferrous salts (Includes Ferro-DSS) ↔ hemoglobin abnormalities

Severe Potential Hazard, High plausibility. Applies to: Hemoglobinopathy, Blood Transfusion

There is no excretory mechanism for iron. Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions. Clinical monitoring of erythropoietic function and ferritin levels is recommended.

References

  1. "Product Information. INFeD (iron dextran)." Schein Pharmaceuticals Inc, Florham Park, NJ.
Major

Laxatives (Includes Ferro-DSS) ↔ inflammatory bowel disease

Severe Potential Hazard, Moderate plausibility. Applies to: Inflammatory Bowel Disease

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

References

  1. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  2. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc, Woodbridge, NJ.
Major

Laxatives (Includes Ferro-DSS) ↔ intestinal obstruction disorders

Severe Potential Hazard, Moderate plausibility. Applies to: Gastrointestinal Obstruction

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

References

  1. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  2. "Product Information. Kondremul (mineral oil)." Bristol-Myers Squibb, Princeton, NJ.
  3. "Product Information. Fleet Babylax (glycerin)." Alcon Laboratorries Inc, Fort Worth, TX.
  4. "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet, Lynchburg, VA.
  5. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc, Woodbridge, NJ.
View all 5 references
Moderate

Ferrous salts (Includes Ferro-DSS) ↔ achlorhydria

Moderate Potential Hazard, Moderate plausibility. Applies to: Achlorhydria

Gastric acidity increases iron bioavailability by maintaining the ingested iron in a reduced form as ferrous ions, which are more readily absorbed than ferric ions. Therefore, when iron therapy is administered orally, higher dosages may be necessary for patients with decreased gastric acid production. Also, a liquid formulation is recommended in these patients because dissolution of the tablet coating depends on normal gastric acidity.

References

  1. "Product Information. Feosol Tablets (ferrous sulfate)." SmithKline Beecham, Philadelphia, PA.
Moderate

Ferrous salts (Includes Ferro-DSS) ↔ gastrointestinal irritation

Moderate Potential Hazard, High plausibility. Applies to: Peptic Ulcer, Colitis/Enteritis (Noninfectious)

Iron can be irritating and damaging to gastrointestinal mucosa. Iron therapy should be administered cautiously in patients with peptic ulcer disease, enteritis, or ulcerative colitis.

References

  1. "Product Information. Feosol Tablets (ferrous sulfate)." SmithKline Beecham, Philadelphia, PA.

Ferro-DSS (docusate / ferrous fumarate) drug interactions

There are 167 drug interactions with Ferro-DSS (docusate / ferrous fumarate)

Ferro-DSS (docusate / ferrous fumarate) alcohol/food interactions

There is 1 alcohol/food interaction with Ferro-DSS (docusate / ferrous fumarate)

More about Ferro-DSS (docusate / ferrous fumarate)

Related treatment guides

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide